CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors
Key Insights
CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC (search) in patients with advanced solid tumors (search).
The trial utilizes CytoMed's patented donor-derived allogeneic cell therapy platform to enhance safety and efficacy.
CTM-ONC (search) targets tumors expressing high levels of certain activating ligands, aiming to improve patient outcomes.
CytoMed Therapeutics has announced the initiation of its first-in-human Phase I ANGELICA clinical trial, evaluating the safety and efficacy of CTM-ONC (search) in patients with advanced solid tumors (search). This trial marks a significant milestone for the company, utilizing its patented donor-derived allogeneic cell therapy platform.
The ANGELICA trial is designed to assess the safety, tolerability, and preliminary efficacy of CTM-ONC (search), an innovative immunotherapy product. CTM-ONC is designed to target and eliminate cancer cells expressing high levels of specific activating ligands. The study aims to enroll patients with advanced solid tumors (search) who have exhausted standard treatment options.
Trial Design and Objectives
The Phase I trial is an open-label, dose-escalation study. The primary objective is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CTM-ONC (search). Secondary objectives include assessing the preliminary efficacy of CTM-ONC based on objective response rate (ORR), disease control rate (DCR), and duration of response (DoR), as well as evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the therapy.
CTM-ONC: A Novel Immunotherapy Approach
CTM-ONC (search) leverages CytoMed's proprietary allogeneic cell therapy platform, which is designed to enhance the safety and efficacy of cell-based immunotherapies. By utilizing donor-derived cells, CTM-ONC aims to overcome some of the limitations associated with autologous cell therapies, such as manufacturing challenges and patient-specific variability.
The therapy is engineered to target tumors expressing high levels of specific activating ligands, which are often upregulated in various solid tumors (search). This targeted approach aims to selectively eliminate cancer cells while sparing healthy tissues, potentially reducing off-target toxicities.
The Need for Innovative Cancer Therapies
Advanced solid tumors (search) remain a significant challenge in oncology, with many patients experiencing disease progression despite available treatments. There is a critical need for innovative therapies that can improve outcomes and extend survival for these patients. CTM-ONC (search) represents a promising new approach to cancer immunotherapy, with the potential to address this unmet medical need.